INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC50s of 30 and 630 nM, respectively.

INT-767 does not show cytotoxic effects in HepG2 cells, does not inhibit cytochrome P450 enzymes, does not inhibit the human ether-a-go-go-related gene potassium channel.is highly stable to phase I and II enzymatic modifications.

INT-767 decreases triglyceride levels and plasma total cholesterol in db/m and db/db mice.

1000403-03-1

C25H44NaO6S

495.67

INT-767

DMSO:205.5 mg/mL (415.44 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years